Descrizione del progetto
Come una gravidanza, anche i tumori potrebbero presto essere rilevati precocemente con un semplice kit di analisi
Il nostro sistema gastrointestinale ospita una fiorente comunità di microrganismi: il microbiota intestinale. Cambiamenti in questo microscopico ecosistema sono stati sempre più spesso collegati a diversi tipi di tumori. Considerato il ruolo critico dell’intestino nel riassorbimento di liquidi e sostanze nutritive nel flusso sanguigno, le attività e i metaboliti del microbiota intestinale influiscono sistematicamente sui tessuti. I biomarcatori del cancro localizzati nell’intestino potrebbero agevolare il rilevamento precoce di anomalie che causano il cancro, e successivamente un trattamento precoce e una prognosi significativamente migliorata. BiomStrip prevede di sfruttare questo potenziale con un semplice sistema di analisi da eseguire in casa, simile a un kit di gravidanza. Il kit potrebbe presto affidare la medicina preventiva nelle mani, e nell’intestino, dei pazienti.
Obiettivo
Cancer is the second leading cause of death globally, causing 1 in 6 deaths. If cancer is diagnosed at early stage, it is highly likely to be treated successfully. Once it has grown and spread, therapy is vastly more difficult and costly, and survival rate drops rapidly. Screening is a vital healthcare element for early detection but suffers from burdens of cost, capacity, compliance, and detection sensitivity problems.
BiomStrip introduces a pioneering screening solution that can carry out cancer screening in the fashion of the common pregnancy tests. Building on our recent breakthrough results in biomarker validation granting TRL6 stage, we have designed a diagnostic device that is low-cost, non-invasive, accurate, can be handled by consumer, and bought over-the counter. The diagnostic method is based on detecting dysbiosis of gut microbial flora, a highly sensitive indicator of pathophysiological processes able to selectively show disease onset at super-early stage, even before histological changes are observable. The method is ultimately able to detect most cancer types and even other diseases, making it a future platform technology.
For highest scalability, fastest time-to-market, explosive growth, low resource-intensity, and minimised risk and overheads, we will license production and commercialisation to established multinational companies, keeping our focus as high-tech SME. Breast cancer will be our market entry point and other diseases will be covered subsequently form own resources.
To engineer this Workplan, a feasibility study will assess entry use cases and their markets, analyse business model and partnership options, and evaluate IPR strategies in a Strategic Business Plan.
The disruptive approach offers to transform cancer screening from top-down to bottom-up: empowering patients, gradually alleviating healthcare systems large effort and sums spent on preventive cancer diagnostics, and drastically improving therapeutical effectiveness.
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
4032 DEBRECEN
Ungheria
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.